The patient should meet the following criteria to get Wegovy coverage for cardiovascular risk reduction: Initial therapy: Wegovy is prescribed to reduce the risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke in an adult with established cardiovascular disease who is also overweight or obese, and
At the 4 mg dose level in the phase 2 trial, participants averaged approximately 3-5% body weight reduction by week four to six
Stop Constant Snacking Many people eat almost continuously: Biscuits Crisps Sugary drinks Sweets Processed snacks This can keep insulin levels elevated all day long
At the end of 40 or 42 weeks (study time varied by trial), urine albumin-to-creatinine ratio (UACR) was significantly reduced among participants assigned to tirzepatide 5, 10, or 15 mg as compared with those assigned to all pooled comparators (placebo, semaglutide, insulin degludec, and insulin glargine) with adjusted mean percent changes of 19.3% [95% CI 12.525.5%], 22.0% [95% CI 15.328.1%], and 26.3% [95% CI 20.032.0%], respectively, with a greater reduction observed in participants with a UACR 30 mg/g at baseline [96]
